FDA Approves First Nonstimulant ADHD Drug for Adults in 20 Years
May 2, 2022Enhertu Obtains Regular FDA Approval After Accelerated Approval
May 4, 2022May 4, 2022 – Phathom Pharmaceuticals’ VoqueznaTM Triple Pack (vonoprazan/amoxicillin/clarithromycin) and VoqueznaTM Double Pack (vonoprazan/amoxicillin) have been approved to treat Helicobacter pylori infection in adults.
- H. pylori bacteria cause infections in the stomach and duodenum (first part of the small intestine) and are the main cause of peptic ulcers. Voquezna Triple Pack and Double Pack co-package antibiotics with a novel acid-blocking medication, vonoprazan, to treat such infections.
- The recommended dosing is as follows:
- Voquezna Triple Pack: Vonoprazan 20mg, amoxicillin 1,000mg, and clarithromycin 500mg each taken twice daily (12 hours apart) for 14 days.
- Voquezna Double Pack: Vonoprazan 20mg taken twice daily plus amoxicillin 1,000mg taken three times daily (morning, mid-day, and evening) for 14 days.
- Both Voquezna Triple Pack and Voquezna Double Pack have a wholesale acquisition cost of $812 per treatment course.